| Contents per vial | 5 mg |
|---|---|
| Form | Lyophilized powder |
| Packaging | Sealed glass vial |
| Purity | 99,94 % (HPLC) |
| Storage | 2–8 °C, keep dry and protect from light |
| Molecular formula | C152H252N44O42 |
| Molecular weight | 3367,95 g/mol |
| Sequence or structure | Tyr–D-Ala–Asp–Ala–Ile–Phe–Thr–Gln–Ser–Tyr–Arg–Lys–Val–Leu–Ala–Gln–Leu–Ser–Ala–Arg–Lys–Leu–Leu–Gln–Asp–Ile–Leu–Ser–Arg–NH2 |
| CAS | 446036-97-1 |
| Intended use | For laboratory research only |
About this product
CJC-1295 without DAC refers to a shorter-acting GHRH-analog molecule without a Drug Affinity Complex. It is being investigated for stimulation of pulsatile growth hormone release and the GH/IGF-1 axis. Without DAC, it does not have the extended albumin binding typical of CJC-1295 with DAC. The research significance lies in the short-term GHRH receptor stimulation.
What is CJC-1295 without DAC?
CJC-1295 without DAC is classified as a “synthetic peptide or peptide analog” and is being evaluated in scientific research in areas such as growth hormone secretion, GH pulsatility, IGF-1. Attention is paid to its interaction with relevant receptors, enzymes or cellular pathways and subsequent changes in measurable laboratory parameters.
Mechanism of action under investigation
The molecule activates the GHRH receptor and cAMP signaling in the pituitary gland. Absence of DAC means shorter circulation and no albumin binding typical of DAC variants.
MAIN AREAS OF RESEARCH
• Growth hormone secretion: CJC-1295 without DAC is a shorter-acting GHRH analog investigated for stimulation of growth hormone release via the GHRH receptor.
• GH pulsatility: Shorter action allows examining the hormonal response closer to individual GH pulses than with the long-acting DAC form.
• IGF-1: Research is looking at how GH stimulation subsequently changes IGF-1 and other indicators of the growth hormone axis.
• Difference from DAC form: Without Drug Affinity Complex, the molecule does not bind to albumin for a long time, therefore it has a different pharmacokinetic profile from CJC-1295 with DAC.
Research findings to date
Results should be assessed according to the level of evidence: cell and animal models. The research significance lies in the short-term GHRH receptor stimulation. In the case of substances affecting the growth hormone axis, for example, reactions at the site of administration, headache, changes in appetite, fluid retention and hormonal changes are monitored in the research.
